Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07122986 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About a Vaccine Against E Coli in Healthy Adults

A Phase 1 study of Healthy Participants, sponsored by Pfizer.

Recruiting
Registry status
Phase 1
Development phase
310
Enrollment target
11
Study locations

NCT07122986: Recruiting Phase 1 study of Healthy Participants, sponsored by Pfizer.

NCT07122986 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Pfizer. The registered enrollment target is 310 participants, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (392% higher). The trial reports 11 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07122986, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
310 participants
Enrollment target
11
Study locations

Study Summary

This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.

Primary Outcome

Prespecified local reactions (redness, swelling, and pain at the injection site) following each vaccination

Conditions Studied

Interventions

  • DRUG E coli vaccine 1 Dose A
  • DRUG E coli vaccine 1 Dose B
  • DRUG E coli vaccine 2
  • DRUG E coli vaccine 3
  • DRUG E coli Vaccine 4 Dose A

Study Locations (11)

California

  • Anaheim Clinical Trials, LLC - Anaheim
  • Orange County Research Center - Lake Forest
  • Diablo Clinical Research, Inc. - Walnut Creek

Tennessee

  • Alliance for Multispecialty Research, LLC - Knoxville
  • Alliance for Multispecialty Research, LLC - Knoxville
  • University Eye Specialists, P.C. (Ophthalmologist) - Maryville

Florida

  • Miami Eye Institute - Hollywood
  • Research Centers of America - Hollywood

Ohio

  • CTI Clinical Research Center - Cincinnati
  • Senders Pediatrics - South Euclid

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 310 participants
Start Date 2025-08-11
Est. Completion 2028-05-26
Phase Phase 1
Pfizer

1,845 total trials

What NCT07122986 shows while recruiting

NCT07122986 is an interventional study that assigns participants to a tested intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (392% higher).

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 5 interventions - of which E coli vaccine 1 Dose A is the first listed.

NCT07122986 lists 11 locations in 5 states (California, Tennessee, Florida).

Frequently Asked Questions

What is clinical trial NCT07122986 about?

NCT07122986 is a clinical study titled "A Study to Learn About a Vaccine Against E Coli in Healthy Adults". This study evaluates an investigational vaccine designed to protect against Escherichia coli (E coli). The primary objective is to assess the safety and tolerability of E coli vaccines administered intramuscularly to healthy adults.

What is the current status of trial NCT07122986?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2025-08-11. Estimated completion is 2028-05-26.

What conditions does trial NCT07122986 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT07122986?

The interventions under investigation include: E coli vaccine 1 Dose A (DRUG), E coli vaccine 1 Dose B (DRUG), E coli vaccine 2 (DRUG), E coli vaccine 3 (DRUG), E coli Vaccine 4 Dose A (DRUG).

Who is sponsoring clinical trial NCT07122986?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07122986 being conducted?

This trial has 11 study locations across California, Florida, New York, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07122986's enrollment target sits among peer trials

310 5th of 119 higher than 115 of 119 other Healthy Participants trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03039439 · 310 participants

    Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors

  • NCT04178018 · 310 participants · NA

    Transvaginal Ultrasound and Photoacoustic Imaging of Ovary

  • NCT04878094 · 310 participants · Phase 3

    A Study of Intra-operative Imaging in Women With Ovarian Cancer

  • NCT05459233 · 310 participants · NA

    Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07122986, the US trial registry maintained by the National Library of Medicine. NCT07122986 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.